PE20001087A1 - Formulaciones de dosis orales que comprenden (2s,3s,5r)-2-(3,5-difluorofenil)-3,5-dimetil-2-morfolinol y acido alginico - Google Patents

Formulaciones de dosis orales que comprenden (2s,3s,5r)-2-(3,5-difluorofenil)-3,5-dimetil-2-morfolinol y acido alginico

Info

Publication number
PE20001087A1
PE20001087A1 PE1999000976A PE00097699A PE20001087A1 PE 20001087 A1 PE20001087 A1 PE 20001087A1 PE 1999000976 A PE1999000976 A PE 1999000976A PE 00097699 A PE00097699 A PE 00097699A PE 20001087 A1 PE20001087 A1 PE 20001087A1
Authority
PE
Peru
Prior art keywords
morpholinol
difluorophenyl
dimethyl
alginic acid
formulations including
Prior art date
Application number
PE1999000976A
Other languages
English (en)
Spanish (es)
Inventor
Samuel Bruce Balik
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20001087A1 publication Critical patent/PE20001087A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE1999000976A 1998-09-28 1999-09-27 Formulaciones de dosis orales que comprenden (2s,3s,5r)-2-(3,5-difluorofenil)-3,5-dimetil-2-morfolinol y acido alginico PE20001087A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10211298P 1998-09-28 1998-09-28

Publications (1)

Publication Number Publication Date
PE20001087A1 true PE20001087A1 (es) 2000-10-20

Family

ID=22288187

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000976A PE20001087A1 (es) 1998-09-28 1999-09-27 Formulaciones de dosis orales que comprenden (2s,3s,5r)-2-(3,5-difluorofenil)-3,5-dimetil-2-morfolinol y acido alginico

Country Status (17)

Country Link
EP (1) EP1117407A1 (fr)
JP (1) JP2002525328A (fr)
KR (1) KR20010075385A (fr)
CN (1) CN1328459A (fr)
AR (1) AR022673A1 (fr)
AU (1) AU6087399A (fr)
BR (1) BR9914096A (fr)
CA (1) CA2345638A1 (fr)
CZ (1) CZ20011142A3 (fr)
HU (1) HUP0103459A2 (fr)
IL (1) IL142054A0 (fr)
MA (1) MA26693A1 (fr)
NO (1) NO20011555D0 (fr)
PE (1) PE20001087A1 (fr)
PL (1) PL346877A1 (fr)
TR (1) TR200100863T2 (fr)
WO (1) WO2000018406A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1220673A2 (fr) * 1999-10-13 2002-07-10 Glaxo Group Limited Methode destinee au traitement de l'obesite
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4597969A (en) * 1982-04-05 1986-07-01 Merck Sharp & Dohme Stabilization of unstable drugs or food supplements
GB8924528D0 (en) * 1989-10-31 1989-12-20 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use

Also Published As

Publication number Publication date
PL346877A1 (en) 2002-03-11
CA2345638A1 (fr) 2000-04-06
TR200100863T2 (tr) 2001-07-23
AR022673A1 (es) 2002-09-04
BR9914096A (pt) 2001-07-31
CZ20011142A3 (cs) 2001-09-12
JP2002525328A (ja) 2002-08-13
WO2000018406A1 (fr) 2000-04-06
HUP0103459A2 (hu) 2002-01-28
NO20011555L (no) 2001-03-27
EP1117407A1 (fr) 2001-07-25
AU6087399A (en) 2000-04-17
IL142054A0 (en) 2002-03-10
MA26693A1 (fr) 2004-12-20
KR20010075385A (ko) 2001-08-09
NO20011555D0 (no) 2001-03-27
CN1328459A (zh) 2001-12-26

Similar Documents

Publication Publication Date Title
MX9207169A (es) Composiciones orales para suprimir olores bucales.
CY1106634T1 (el) Θεραπευτικα παραγωγα της πιπεραζινης
ES2190674T3 (es) Uso de n-alquil derivados de cadena larga de desoxinojirimicina para la fabricacion de un medicamento para el tratamiento de enfermedades de acumulacion de glucolipidos.
GR3031135T3 (en) Compositions containing S(+)-Ibuprofen.
YU23599A (sh) Stabilizovani antihistaminski sirup
RU94044436A (ru) Способы подавления атрофии кожи и влагалища
FI943315A0 (fi) Farmaseuttinen valmiste pore- ja/tai hajoamistabletin tai pikarakeiden muodossa, samoin kuin menetelmä valmistaa niitä
BR9810312A (pt) Composição farmacêutica que apresenta atividade antitumoral acentuada e/ou efeitos colaterais reduzidos contendo um agente antitumoral e um derivado do ácido hidroxìmico
HUP9702345A2 (hu) 3-Hidroxi-piridin-2-karbonsav-amid-észter-származékok, eljárás előállításukra, e vegyületeket tartalmazó gyógyszerkészítmények és alkalmazásuk
KR880006193A (ko) 피페리딘 화합물 및 그의 제조 및 용도
AU6593301A (en) Compounds with a sulphonamide group and pharmaceutical compositions containing these compounds
UY24308A1 (es) Tabletas exentas de aglutinante que contienen tramadol o una sal de tramadol, para administracion oral
SE9901573D0 (sv) New compounds
RU94044456A (ru) Средство для подавления дисфункционального маточного кровотечения
PT77991B (en) Process for the preparation of benzoylurea compounds and pesticidal and pharmaceutical compositions comprising same and for their utilization in the control of insects and/or acarids and for combating tumors in living beings respectively
ATE157252T1 (de) 3'-azido-2',3'-dideoxy-5-methylcytidin enthaltende antivirale zusammensetzungen
TR200000153T2 (tr) İl-5 inhibite eden 6-azaurasil türevleri.
BR0311642A (pt) Formulação de divalproex de sódio de liberação aumentada
PE20001087A1 (es) Formulaciones de dosis orales que comprenden (2s,3s,5r)-2-(3,5-difluorofenil)-3,5-dimetil-2-morfolinol y acido alginico
KR890006625A (ko) 2,2-디메틸크로멘 유도체, 그의 제조방법 및 그것을 함유하는 약학 조성물
CY1104974T1 (el) Χρηση παραγωγου του διφωσφονικου οξεος για τηn παρασκευη ενος φαρμακου που προοριζεται για τη θεραπεια της χωλοτητας
HUP9903410A2 (hu) Tolfenámsavat vagy gyógyszerészetileg elfogadható sóját tartalmazó, gyors hatóanyag-leadású tabletta
PT913151E (pt) Composicoes de luta contra a helicobacter pylori que contem derivados de 1-metilcarbapenem como substancia activa
ES475533A1 (es) Un metodo para la preparacion de formas racemicas y optica- mente activas de 2-(4-difenilil)-n-(dimetilamino-alquil)pro-pionamida
ES2123808T3 (es) Derivado de acilfenilglicina y agente profilactico y curativo para enfermedades causadas por una actividad acrecentada de colagenasa, que contiene dicho compuesto como ingrediente activo.

Legal Events

Date Code Title Description
FD Application declared void or lapsed